#United States #Las Vegas #Upsher-Smith #Duchenne Muscular Dystrophy #Deflazacort Tablets

Upsher-Smith's Commitment to Duchenne Muscular Dystrophy Community

Upsher-Smith Laboratories, LLC, a prominent player in the pharmaceutical industry, has announced its participation in the 2025 Parent Project Muscular Dystrophy (PPMD) Annual Conference set to take place from June 19 to 21 in Las Vegas, Nevada. This event serves as a significant platform for stakeholders in the Duchenne muscular dystrophy (DMD) community, aiming to foster connections and provide valuable information.

At the conference, representatives from Upsher-Smith will be available at the resource fair to discuss their pioneering work in providing support and resources centered around their Deflazacort Tablets. These tablets are an essential treatment option for patients diagnosed with DMD, a rare genetic disorder that primarily affects boys and leads to progressive muscle degeneration.

Jim Maahs, the Head of Commercial for Upsher-Smith, elaborated on the company's long-standing commitment, stating, "Experience matters in rare disease. Founded in 1919, we have dedicated over a century to serving patients and their distinct needs within rare disease communities. We invite all attendees to learn how we are elevating the standard of support for DMD patients and their families."

Upsher-Smith has established itself as a trustworthy partner in the pediatric rare disease arena. This commitment is highlighted through their offering of high-quality generic medications. The Deflazacort Tablets from Upsher-Smith are specifically designed to provide the same therapeutic benefits as other branded medications while maintaining an equally high level of support services. This not only helps to improve patient accessibility to essential treatments but also assures families that they are receiving comparable quality care.

About Deflazacort Tablets

Deflazacort Tablets by Upsher-Smith are classified as an AB-rated generic version of the branded drug Emflaza® (deflazacort). Both medications contain identical active ingredients and dosage strengths, ensuring that patients receive effective treatment for DMD. The tablets are available in various strengths, including 6 mg, 18 mg, 30 mg, and 36 mg, making it easier for physicians to tailor dosages to individual patient needs. This flexibility is crucial for managing DMD, particularly as patients grow and their treatment requirements evolve.

Providing essential information about medication usage is a priority for Upsher-Smith. The company advises caution with Deflazacort, highlighting possible side effects and safety warnings that may arise during administration. These include potential impacts on endocrine function, immunosuppression, and alterations in cardiovascular function, among others. Upsher-Smith emphasizes the importance of monitoring patients for adverse reactions and ensuring they receive comprehensive care.

Patients, caregivers, and healthcare providers can refer to the Prescribing Information for Deflazacort Tablets for detailed insights and guidance. They are also encouraged to report any adverse reactions to Upsher-Smith directly or to the FDA.

A Historic Commitment

Upsher-Smith's ongoing dedication to improving health outcomes for patients with rare diseases can be traced back over a century. Their foundational principle is to foster solid relationships within the healthcare community while maintaining a focus on product quality and versatility. As a member of the Bora Group, the company is poised to broaden its reach and impact in the realm of pharmaceutical manufacturing, promising to uphold high standards of care and reliability.

The PPMD Annual Conference represents an opportunity for Upsher-Smith to not only showcase their products but also to forge lasting partnerships and connections within the DMD community. By participating actively in such influential events, Upsher-Smith reinforces its commitment to operating as a dependable ally for families navigating the complexities of managing Duchenne muscular dystrophy.

For further information on Upsher-Smith and its offerings, visit www.upsher-smith.com.